Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 10/20 | 0.81 |
| ▸ | CPT1B | Q92523 | 9/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905149 | 0.89 | CPT1A (1.00) | CPT1ACPT1BMAPTSMN1; SMN2 | |
| SCHEMBL2898474 | 0.89 | CPT1A (0.82) | CPT1ACPT1BALDH1A1TSHRLMNA | |
| SCHEMBL750932 | 0.88 | CPT1A (0.81) | CPT1ACPT1BALDH1A1TSHRLMNA | |
| SCHEMBL27762332 | 0.87 | CPT1A (0.84) | CPT1ACPT1BLMNAMAPTSMN1; SMN2 | |
| SCHEMBL2898313 | 0.86 | CPT1A (0.84) | CPT1ACPT1BALDH1A1 | |
| SCHEMBL2904429 | 0.82 | CPT1A (0.85) | CPT1ACPT1BALDH1A1 | |
| SCHEMBL753351 | 0.80 | CPT1A (0.84) | CPT1ACPT1BALDH1A1TSHRLMNA | |
| SCHEMBL2898231 | 0.79 | CPT1A (1.00) | CPT1ACPT1BLMNAMAPTSMN1; SMN2 | |
| SCHEMBL2906465 | 0.78 | CPT1A (0.85) | CPT1ACPT1BALDH1A1TSHRLMNA | |
| SCHEMBL3838204 | 0.78 | CPT1A (0.84) | CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799933-B2 | Sulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | CPT1A, SULT2A1, SULT1A1 | CPT1A 1/4885CPT1B 5/4885ALDH1A1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.